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Issues and Current Applications of
Interspecies Extrapolation of Carcinogenic
Potency as a Component of Risk
Assessment
by Willard J. Visek*
The Life Sciences Research Office (LSRO) of the Federation of American Societies for Experimental
Biology (FASEB) is conducting this symposium under contract with the Center for Food Safety and
Applied Nutrition (CFSAN) of the Food and Drug Administration (FDA). The FDA has requested infor-
mation on the strengths and weaknesses of current interspecies extrapolation methods using metabolic
and pharmacokinetic data, identity of data for these methods, bases for choice of extrapolation method
and selection of data base, validity and uniformity of interspecies extrapolation from target organ data,
and nature and completeness of supporting data. Definitions and basic concepts of dose scaling are ad-
dressed and questions regarding appropriate units of measurement (e.g., mg/kg body weight, mg/m3 res-
pired air, mg/m2 surface area) are raised. The use of DNA damage as a marker or end point upon which
to scale carcinogenic potency is considered. Genotoxic mechanisms of carcinogenesis are emphasized
because the roles of DNA adducts and DNA repair processes in initiation and promotion are much better
defined than the mechanism for nongenotoxic carcinogenesis. The problems encountered in evaluating
the human carcinogenicity oftrichloroethylene are reviewed. The broad objectives ofthe symposium are
discussed and the development of a structured format for the presentation of invited papers is presented.
Introduction
By mandate ofthe 96th Congress, the Food and Drug
Administration was directed to contract with the Na-
tional Academy of Sciences for a study on the institu-
tional means of risk assessment. In 1983, a report en-
titled "Risk Assessment in the Federal Government:
Managing the Process" was delivered to FDA by the
Commission on Life Sciences of the National Research
Council (1). In that report the risk assessment process
was characterized bythe followingfoursteps: (a) hazard
identification, (b) dose-response assessment, (c) expo-
sure assessment, and (d) risk characterization.
In carcinogenic riskassessment, the second step (i.e.,
dose-response assessment) estimates the dose associ-
ated with acceptable levels of risk in humans on the
basis of high-dose cancer incidence data from animal
experiments. Such estimates are made from intraspe-
cies extrapolation of high-dose incidence to low-dose
incidence and by the conversion of dose estimates in
animals to equivalent or equipotent estimates of dose
in humans. The estimation oflow-dose incidence on the
basis of high-dose data within the same species is de-
fined as dose-range extrapolation. Various mathemati-
cal models are used to make these calculations. Con-
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version ofanimal dose to human dose (i.e., interspecies
extrapolation) is defined as dose scaling. Dose scaling
may refer to animal-to-animal as well as animal-to-hu-
man. We will furtherdefine a scalingfactor as any char-
acteristic ofatest species orinvitro systemthat isused
as a common denominator for dose scaling.
The purpose ofthis symposium is to examine the biol-
ogic bases for developing effective dose-scaling proce-
dures. Dose-range extrapolations and the mathematical
and statistical models fromwhich they are derived have
been reviewed in a number ofother forums and will not
be directly addressed in this symposium.
An advisory committee to the Food and DrugAdmin-
istration, commenting on downward extrapolation from
results obtained at some level well above the level of
actual use, said, "The basic problem is that extrapola-
tion outside the range of observation must be based on
generally unverifiable assumptions about the mathe-
matical nature of the dose-response relationship near
zero dosage" (2). It is not certain that the situation has
improved in the last 15 years. The FDA has asked the
Life Sciences Research Office toinvestigate the validity
and utility of current procedures for interspecies ex-
trapolation ofdatafromanimalstudies offood chemicals
to the estimation ofchemical carcinogenesis in humans.
Our examination ofthese topics in the papers and sup-W. J. VISEK
plemental presentations that follow will be guided by
the following questions posed by FDA:
* What are the existing methods for interspecies ex-
trapolation based on qualitative and quantitative dif-
ferences between test species and man?
* What are the strengths and weaknesses of the data
bases supporting these methods?
* What circumstances make one data base or extrapo-
lation method more informative than another?
* Do existing data on target tissues provide a uniform
method for extrapolating carcinogenic potency data
for all substances and all species to man? If so, what
are the nature and extent of these data bases, and
what additional data are needed?
Itshouldbeemphasizedthatthissymposium, inorder
to be most effective in providing useful information for
the FDA and answering the questions the agency has
posed, will focus on biological data and concepts and not
on mathematical modeling or statistical approaches to
extrapolation ofhigh-dose to low-dose effects.
Although we are primarily interested in assessment
of the carcinogenic risk of food chemicals, we do not
want to exclude any pertinent information from exper-
iments in acute and chronic toxicity involving other end
points. Frequently, throughout the symposium, ex-
amples will be drawn from the general toxicology lit-
erature in order to illustrate a particular point; how-
ever, the principal concern is human dietary exposure
to carcinogens.
Dose Scaling: Test Animals to
Humans
This symposium will focus on several aspects ofdose
scaling between test species and humans. The topics
are as follows: definition ofscalingand scalingfunctions;
differentiation of dose-range extrapolation and dose
scaling; commonmethods ofscalingbased onbodymass,
surface area, and dietary intake; biological bases ofcur-
rent methods and their relationship to mechanisms of
carcinogenesis; strengths and weaknesses of current
scaling procedures.
In addition, there are also several specific concerns
and issues that relate to the discussion ofthese topics.
(a) Does the choice of end point (i.e., carcinogenesis
rather than acute toxic effect) have a significant impact
on the application of scaling methods? What problems
may arise when interspecies extrapolations are at-
tempted inthe absence ofknowledge ofacommonmech-
anism ofcarcinogenicity among species? (b) Is it appro-
priate to compare dose-response curves between spe-
cies when there is a significant difference in the slope
function ofthe curves? Does a difference in slope func-
tion necessarily imply differing mechanisms of carcin-
ogenicity that make accurate scaling impractical? (c)
Should dose scaling between species be based on ad-
ministered dose or on a quantitative estimate of cu-
mulative target tissue exposure [e.g., tissue concen-
tration integral (TCI) in micromoles x minutes x li-
ters-l]? (d) Are the statistical procedures currently
used for comparisons of carcinogenic potency between
species being appropriately applied?
In this context it could be especially useful for FDA
to explore dose-scaling methods based upon total ex-
posure ofthe targettissues ratherthanon administered
dose with the expectation that improved correlations
with cancer-causing exposures in humans might be
found.
Figure 1 illustrates the problem to be addressed in
this symposium by identifying the problems that sci-
entists face in scaling potency data among species. The
coordinates in Figure 1 are labeled only in the generic
sense, identifying neither independent nor dependent
variables. The reason for not specifying these coordi-
natesisthatatthistimewedonotknowwhichofseveral
independent variables is most useful orwhich ofdozens
of end points is most valid.
In Figure 1, the solid line (curve 1) represents the
response of one species (A) to a range of dosage con-
ditions measured in milligrams/kilograms. This curve
represents an unacceptable response forthe species be-
cause the proportion of the exposed population which
has been affected is in excess ofa minimal background
level. The horizontal dashed line represents the re-
sponse ofa second species (B) to dosages overthe same
range as depicted in curve 1. Curve 2 ofthe dashed line
illustrates an acceptable response because the response
remains near the minimum risk level. If the exposure
conditions are extended as shown in curve 3 of the
dashed line, we would expect to find a range ofdosages
that is also unacceptable for this species B.
The fallacy ofusing curve 1 to try to predict curve 2
in the absence of any knowledge about curve 3 is ob-
vious. Although these curves are totally hypothetical,
they are not an unreasonable model for trichloroethy-
lene (TCE)inductionofmouselivercancerandtheques-
tionable carcinogenicity of TCE in humans.
If curve 3 represents the population that cannot be
exposed, except epidemiologically, and simultaneously
is the population that one is trying to protect, how can
this dilemma be resolved? This symposium is intended
to examine the basicbiologic characteristics ofdifferent
species that affect our ability to identify response end
points and scaling factors that either minimize the gap
between curves 1 and 3 or atleastreducethevariability
oftheirrelativepositionsforabroadrangeofendpoints
from initial DNA defect to metastatic disease.
Of the many classic examples that can be used to
illustratetheproblemsofmilligramperkilogramscaling
between species, one was reviewed in some detail by
Calabrese (3) based on a quotation from Schmidt-Niel-
sen's 1972 book, How Animals Work (4). In reference
to an article published in Science about dosing an ele-
phant with LSD to produce a rage reaction, Schmidt-
Nielsensaid, "Theauthorshadcalculatedthedosebased
on the amount that puts a cat into a rage, and had
multiplied it up by weight until they arrived at 297 mg
of LSD to be given to the elephant. After the injection
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FIGURE 1. Comparison of a hypothetical dose-response curve for Species A(-) and Species B (---).
of297 mgthe elephant immediately started trumpeting
and running around, then he stopped and swayed; five
minutes after the injection he collapsed, went into con-
vulsions, defecated and died." There is no evidence that
this experiment has been or is likely to be replicated at
lower doses, so we will probably never know if the al-
ternate scaling factors computed by Calabrese would
have ensured a more satisfactory outcome (Table 1).
Experiences such as those with the elephant and cat
strongly suggest that the relationship between curves
1 and 3 in Figure 1 is not likely to be constant on a
milligram per kilogram basis between any two test spe-
cies nor between test species and man. Such relation-
Table 1. Projected dose of LSD required to induce rage
in an elephant.a
Dose, mg Basis for calculation
0.4 Brain size ratio (elephant:human) and effective
dose (human)
3.0 Metabolic rate ratio (human:elephant) and
effective dose (human)
8.0 Body weight ratio (elephant:human) and
effective dose (human)
80.0 Metabolic rate ratio (cat:elephant) and effective
dose (cat)
297.0 Body weight ratio (elephant:cat) and effective
dose (cat)
aModified from Calabrese (3).
ships are not expected to hold for different chemicals,
nor for all routes ofadministration of a single chemical,
and usually not even for the same chemical by the same
route ofadministration. For some classes ofcompounds
the gap between the curves has been reduced or elim-
inated by using other scaling functions, such as dose
per unit body surface area or dose as a constant per-
centage ofdiet. However, there is no scalingfactorthat
is consistently reliable. The objective ofthis study is to
identify the factors and conditions responsible for the
gap between the dose-response curvesfordifferent spe-
cies and to explore potential solutions to the problem
of identifying valid and useful scaling factors.
In addition to physical parameters such as body mass
and surface area, time has also been identified as a sig-
nificant variable for consideration in scaling. Rall (5)
noted that the lifespan of a human is approximately 35
times that of a mouse and that one man may represent
between 160 to 3000 mice in terms of the number of
cells susceptible to carcinogens. In a summary of tes-
timony on interspecies extrapolation, the lifetime
chance of a single cell being hit by a carcinogen was
estimated to be approximately 100,000 times as great
for a human as for a mouse based on the product of 35
x 3000 (6). Although assumptions of this nature are
not used directly as scaling factors, they do imply a
significant difference in sensitivity as a function ofbody
size (number of cells) and longevity.
Max
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SchwartzandMoore (7)reportedinvitroexperiments
modeling the earliest stages of carcinogenesis, as we
currently understand them, and suggested a diametri-
cally opposed probability of risk as a function of cell
mass and longevity. They studied the capacity of cul-
tured mammalian fibroblasts to metabolize dimethyl-
benz[a]anthracene (DMBA) to yield a mutagenic me-
tabolite. Figure 2 demonstrates substantial differences
between species in the proportion of mutants formed
by fibroblast cultures as a function of carcinogen con-
centration or dosage. At first glance the inverse cor-
relationofresponseandphysicalsizeoftheintactanimal
is remarkable; however, the comparison of human fi-
broblast susceptibility with that for the elephant sug-
gests that body size is probably not the most appro-
priate correlate. The relationship between the horse,
human, and elephant data shown in the graph corre-
spondsmuchmorecloselywithspecieslifespan and met-
abolic rate. However, the response ofhumanfibroblasts
is so nearly zero that there is a built-in bias against
demonstrating a difference between them and fibro-
blasts of an elephant. Shank and Barrows (8) propose
that mammalian cell-mediated mutagenesis is a simpli-
fied method ofrapidly obtaining a quantitative measure
of the relative potency for initiating carcinogenesis.
Langenbach et al. (9) and Jones et al. (10), using V79
cells with hamster or rat hepatocytes, respectively,
were able to correlate the mutagenicity of many com-
pounds with theircarcinogenic potency. Forcompounds
requiring activation by endogenous metabolic pro-
cesses, dosage computation as some function oflifespan
may be useful.
Another factor that contributes to the present un-
certainty of scaling potency data between animals and
humans is the duration of the animal experiments and
the latency of tumors as a function of dose. Jones and
Grendon (11) have proposed a simple inverse cube root
function relating dose to latency. For example, a 1000-
foldincrease indoseresultsina90%decreaseinlatency.
The question therefore arises when one attempts to
scale potency data based on lifespan. What impact does
the change in absolute dose between species have on
the latency of tumor appearance?
Scaling may be further complicated by differential
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FIGURE 2. Mutations in cultured fibroblasts induced by metabolites
of 7,12-dimethylbenz[a]anthracene (DMBA) (7).
responses to total dose versus dose rate. For example,
ifadaily doserate of2mg/kg/dayisusedoveralifespan,
the total dose administered will vary with longevity. If
the experiment is designed to deliver afixed total dose,
the number of fractional doses and their size are vari-
ables that may have a significant impact on the
result (12). It should be noted that the cumulative dose
over time is not, by itself, a reliable method for scaling
carcinogenic potency. Yanysheva and Antomonov in
1976 observed increasing latency oftumor development
with decreasing total dose, but also saw an increased
incidence of tumors as the number offractional admin-
istrations approached a predetermined total dose. Sim-
ilarly, when Pike (13) compared lung cancer rates in 60-
year-old cigarette smokers who had smoked 30 ciga-
rettes/day from age 20 to 40 years with those who had
smoked 15 cigarettes/day from age 20 to 60 years, the
longer exposure to a comparable total dose was asso-
ciated with a 10-fold higher rate than the shorter, more
intense exposure. The results led to much debate but
little concurrence on the reliability of extrapolations of
biochemical or epidemiological data except as compo-
nents ofmultidisciplinary studies (14).
Flamm and Lorentzen (15), in their introduction to
Mechanisms and Toxicity of Chemical Carcinogens
and Mutagens, suggest that many kinds ofcarcinogens
share a common mechanism. This involves biochemical
or enzymatic conversion of the original chemical to ac-
tive electrophiles that form adducts at the nucleophilic
centers ofproteinsandnucleicacids. DNAadducts often
damage DNA, and, if unrepaired, there can be repli-
cation ofthe altered DNA leading to transformed cells
that are forerunners ofcancer. Hoeletal. (16) described
a nonlinear pharmacokinetic model of this process in-
cluding covalent binding of the activated species and
mechanisms of DNA repair. Van Ryzin (17) incorpo-
rated elements ofthe activated electrophile mechanism
into a model of nonlinear kinetics for estimating the
effective dose at the target site and derived a trans-
formed or calculated dose for extrapolating virtually
safe doses for vinyl chloride and saccharin. This model
is consistent with aone-hit mechanism atthe target site
relative to a calculated TCI, rather than administered
dose and with nonlinear metabolic activation of vinyl
chloride ornonlinear, saturablebladderclearance ofsac-
charin.
Other classes of chemicals, which are not converted
to electrophiles and are not genotoxic, nevertheless can
cause cancer. These compounds, which have not been
shown to bind extensively to DNA, are called nongeno-
toxiccarcinogens. Theyappeartobe effectiveonly after
prolonged exposures at doses sufficient to produce
either significant long-term depression of cellular
growth rate or cell death.
Purchase (18), reviewingtheresearch ofElcombe (19)
and Green and Prout (20), notes that pure trichloro-
ethylene is only marginally mutagenic or nonmutagenic
and binding of metabolites to DNA occurs only at in-
significant levels. Mice given 1000 mg/kg/dayby gavage
developed hepatocellular carcinomas, but these doses
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caused no hepatocarcinogenicity in two strains of rats.
Both species metabolize TCE to trichloroacetic acid
(TCA). However, in rats the metabolism reaches sat-
uration at 500 mg/kg, whereas inmice the limit exceeds
2000 mg/kg TCE. Consequently, in mice given 1000
mg/kg, the blood level of TCA is 7 times greater than
in rats similarly dosed. Doses of TCA above 50 mg/kg
produce peroxisomal proliferation in the livers of both
species, but because of the metabolic differences only
mice develop peroxisomal proliferation following TCE.
Invitro, mousehepatocytesproduce30timesmoreTCA
from TCE than do rat hepatocytes, and the latter are
3 times more active than human hepatocytes. Those
observations suggest that TCE is carcinogenic via a
nongenetic (i.e., no chromosomal damage) mechanism
that involves stimulated production of hepatic peroxi-
somes. Humans convert TCE to TCA at only 1/90 of
the rate of mice and peroxisomes do not proliferate in
humans with known TCE exposure. These metabolic
data suggest that humans may not be susceptible to
TCE carcinogenicity. The evidence also suggests that
there is a threshold dose for carcinogenicity even in
susceptible species.
Although it is now fairly well accepted that there are
both frank genotoxic and apparent nongenotoxic mech-
anisms for the induction of neoplasms, scientists have
focused on genotoxic pathways for several reasons: the
mechanisms are generally better defined; the materials
ofconcern include food chemicals, which are more likely
to act by this mechanism; the pathways are more ame-
nabletobiochemical, pharmacological, andphysiological
definition; and there is also a reasonable body of evi-
dence for a multistage process that begins with normal
somatic cells and eventually results in one or more al-
tered clones ofindividual transformed cells.
The array of variables affecting each stage of this
process introduces great difficulty in identifying a sim-
ple relationship between administered dose and ulti-
mate tumor incidence. The myriad ofmechanisms pro-
posed for the development ofneoplasms makes reliable
scaling difficult.
If there is to be significant progress in scaling equi-
potent exposures betweentest species andhumans, em-
phasis will have to be placed on isolating critical ele-
ments of the process for definitive study. It will be
necessary to advance ourknowledge beyond the ability
of treating intact animals with chemicals and then dis-
membering them as black boxes to see what has hap-
pened. There is a need to develop and enhance our abil-
ity to understand the processes that take place and to
applythis understanding in the solution ofscalingprob-
lems.
Papers Commissioned for This
Symposium
The commissioned papers presented at this sympos-
ium provide a review of available information and ap-
proach to extrapolation and dose scaling. In the first
paper, Dr. Calabrese discusses theinfluence ofdiffering
degrees ofheterogeneity in exposed populations on the
effectiveness ofscaling techniques. An overview ofthe
capacity of animal models to predict the responses of
humans to carcinogenic agents is described. The focus
of this presentation is on the comparative biology of
significant test species and humans with regard to bio-
chemical characteristics that affect the response to car-
cinogens.
The followingthree presentations dealwith interspe-
cies comparability at progressive stages of the overall
process of carcinogenesis. The first, presented by Dr.
Standaert, addresses basic pharmacokinetics and phys-
iological modeling. He discusses several examples of
cumulative target tissue exposure as a quantitative
expression ofdose as opposed to administered quantity
or inhaled concentration. The significance of common
biochemical and biophysical mechanisms in the kinetics
of chemical interactions with test species and humans
is also described.
Intranuclear events involving DNA damage and re-
pair and replication ofaltered genetic material to begin
a new cell line of transformed genotype are discussed
by Dr. Slaga. He also reviews the cytoplasmic and nu-
clear genetic mechanisms in test species and humans
which have a significant impact on variation in carcin-
ogenic response at equivalent target tissue exposure
levels.
Dr. Scarpelli reviews mechanisms of posttransfor-
mation promotion and progression leading to manifes-
tation of neoplasms. Comparisons between organs and
between species of the histopathologic changes follow-
ing various exposures to carcinogenic substances are
presented with discussion of the biological bases for
similar and differing responses.
The qualitative and quantitative considerations in in-
terspecies extrapolation as they relate to current prac-
tices of risk assessment are reviewed by Dr. Clayson.
His paper describes interspecies susceptibility to car-
cinogens, the impact of high background levels of tu-
morigenesis in untreated animals on assessment ofthe
response, and the significance of maximum tolerated
dose in the extrapolation of animal data to humans.
Drs. Gibson and Starr present an overview ofpoten-
tial applications of pharmacokinetic and cellular level
mechanisms for more effective interspecies scaling of
carcinogenic potency. This paper explores some of the
emerging methods and opportunities to improve the
state-of-the-art in extrapolating animal carcinogenicity
data to the prediction of cancer in humans. This pre-
sentation considers the role of metabolic, pharmacoki-
netic, and genetic information from target tissues in
various species in the identification of mechanisms
which can improve risk assessment models.
The present day policies and procedures ofthe Food
and Drug Administration for controlling deliberate or
incidental food additives are still derived directly from
the Food and Drug Act of 1906 as construed by the
Supreme Court in 1914. The Court held that the FDA
must only find a reasonable possibility of injury to
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health, because a small amount of an otherwise dele-
teriousingredient maynotbeharmful (21). Thisconcept
of"reasonable possibility ofinjury" is beinginterpreted
by the Agency and the courts to permit carcinogenic
contaminants at a "generally recognized level of insig-
nificant riskto human health." Experience inthe courts
suggeststhatfood contaminants posingalifetimecancer
risk of less than one in a million for an individual are
acceptable provided the supporting data are of good
quality. Taylor (22) points out that it is the consistency
ofcurrent methods to overestimate riskthat makes the
procedures acceptable. The acceptability of extrapola-
tion procedures depends on several factors.
Whenavailable, considerationshould begivento such
matters as the strength ofthe evidence underlying the
basic finding ofcarcinogenicity; the human relevance of
the animal results; comparative metabolism; the mech-
anism ofaction; the dose-response relationship; the pos-
sibility of a threshold; and the true nature of human
exposure as affected, for example, by man's metabolic
handling ofthe substance.
The ultimate task for the FDA is making decisions
on the safety of trace amounts of potentially cancer-
causing chemicals in our diets. The usefulness of the
scientific information which contributes to those deci-
sions rests with the individual scientists who generate
it. We have a common responsibility to make that in-
formation as practically useful and accurate as possible.
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